

February 9, 2024
Symbio Pharmaceuticals Limited
Fuminori Yoshida
Representative Director
President and Chief Executive Officer
(Securities Code: 4582)

**Notice of Recognition of Impairment Loss, and Differences between
Consolidated Earnings Forecasts and Actual Results for FY2023**

Symbio Pharmaceuticals Limited (the “Company”) today announced recognition of impairment losses in the fourth quarter accounting period of the fiscal year ending December 2023 (October 1, 2023 to December 31, 2023), and differences between the full year Consolidated Earnings Forecast announced on November 14, 2023 and the Actual Results announced today, as follows:

1. Recognition of Impairment Loss

In the fiscal year ended December 31, 2023, the Company recognized an impairment loss of 485 million yen due to impairment on certain assets (“Buildings”, “Tools, Furniture and Fixtures”, “Software” and “Leasehold and Guarantee Deposits”) based on a review of recoverability in accordance with the Accounting Standard for Impairment of Fixed Assets.

2. Differences between Consolidated Earnings Forecast and Actual Results for FY 2023

(1) Earnings Forecast and Actual Result for FY 2023 (January 1, 2023 to December 31, 2023)

	Net Sales	Operating Profit	Ordinary Profit	Profit attributable to owners of parent	Earnings per share
	Yen millions	Yen millions	Yen millions	Yen millions	Yen
Previous Forecast (A)	5,603	(680)	(549)	(1,291)	(32.53)
Actual Results (B)	5,589	(811)	(728)	(1,962)	(49.19)
Difference (B-A)	(13)	(132)	(179)	(671)	—
Percentage Change (%)	(0.2)	—	—	—	—
[Reference] Prior Year Results (FY 2022)	10,008	1,963	1,999	1,179	30.20

(2) Reasons for Differences with Consolidated Earnings Forecast

The operating loss result of 811 million yen is greater than the loss previously forecasted, primarily due to quality issues in certain batches of TREAKISYM® that occurred in June 2023. An additional factor was an increase in general and administrative expenses due to higher R&D costs.

Ordinary loss is 728 million yen. The 179 million difference compared to the previous forecast is due to a decrease in operating income and a write-down of foreign currency denominated assets caused by the rapid appreciation of the yen from November 2023 to the end of the fiscal year.

Loss attributable to owners of parent is 1,962 million yen. The difference compared to the previous forecast is due to the impairment loss of 485 million yen on assets that is described in item 1 above.

[Contact]

Investor Relations

Tel: +81(0)3 5472 1125